RecruitingPhase 2NCT07171112

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis


Sponsor

Mayo Clinic

Enrollment

45 participants

Start Date

Nov 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bupropion 150 mg twice daily, a drug called Increased Varenicline Dosing (1mg TID), and others for people with pancreatitis, acute, pancreatitis, chronic, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGStandard Varenicline Dosing (1 mg BID)

Varenicline PO (oral) 1mg twice daily

DRUGBupropion 150 mg twice daily

Bupropion 150 mg PO twice daily

DRUGIncreased Varenicline Dosing (1mg TID)

Varenicline 1mg PO (oral) three times daily


Locations(1)

Mayo Clinic

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07171112


Related Trials